Panelists discuss how 2 key clinical trials, Checkmate 067 and RELATIVITY-047, established the efficacy of different immunotherapy combinations while highlighting the significant difference in toxicity profiles between ipilimumab plus nivolumab (60% grade 3/4 toxicity) versus relatlimab plus nivolumab (19% grade 3/4 toxicity).
Of Interest
Derm Dispatch: Advocating for Skin and Nail Health to Spread Melanoma Awareness
In the latest installment of Derm Dispatch for Dermatology Times, Renata Block, MMS, PA-C, spoke with Karolina Jasko, a melanoma survivor and advocate for skin health, highlighting the importance of melanoma awareness.
Spot On: Sylvester Comprehensive Cancer Center’s Novel Discoveries and Treatments Advance Melanoma Care
Doctors and researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, are making encouraging inroads in the treatment of melanoma, the deadliest form of skin cancer.
Clinical Perspectives: Single-Agent Vs Combination Immunotherapy for Melanoma
Panelists discuss how monotherapy may still be appropriate for certain patient populations including those with desmoplastic melanoma, solid organ transplants, severe autoimmune disease, and older patients where the toxicity risk of combination therapy may outweigh benefits.